Literature DB >> 18837948

Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease.

Bernd Schmidt1, Sabine Weickmann, Christian Witt, Michael Fleischhacker.   

Abstract

In several papers an increased quantity of cell-free plasma DNA as well as the presence of long DNA fragments in cell-free plasma and serum has been described. We isolated cell-free DNA from plasma, serum, and bronchial lavage supernatants from 33 lung cancer patients and 27 patients with a benign lung disease. The DNA was amplified by real-time PCR, and the quantity as well as the DNA integrity was determined. We did not find significant differences between the patient populations. Our results led us to conclude that this method is not useful in a diagnostic setting and is not able to differentiate between lung cancer patients and patients with a benign lung disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18837948     DOI: 10.1196/annals.1448.034

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  19 in total

Review 1.  Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer.

Authors:  Paola Ulivi; Rosella Silvestrini
Journal:  Cell Oncol (Dordr)       Date:  2013-11-01       Impact factor: 6.730

2.  Diagnostic relevance of plasma DNA and DNA integrity for breast cancer.

Authors:  Oliver J Stötzer; Julia Lehner; Debora Fersching-Gierlich; Dorothea Nagel; Stefan Holdenrieder
Journal:  Tumour Biol       Date:  2013-09-10

3.  Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer.

Authors:  Azza M Kamel; Salwa Teama; Amal Fawzy; Mervat El Deftar
Journal:  Tumour Biol       Date:  2015-12-18

4.  Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer.

Authors:  Carina Roth; Sabine Kasimir-Bauer; Klaus Pantel; Heidi Schwarzenbach
Journal:  Mol Oncol       Date:  2011-02-24       Impact factor: 6.603

5.  Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer.

Authors:  Florent Mouliere; Safia El Messaoudi; Dalong Pang; Anatoly Dritschilo; Alain R Thierry
Journal:  Mol Oncol       Date:  2014-03-24       Impact factor: 6.603

6.  Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts.

Authors:  Alain R Thierry; Florent Mouliere; Celine Gongora; Jeremy Ollier; Bruno Robert; Marc Ychou; Maguy Del Rio; Franck Molina
Journal:  Nucleic Acids Res       Date:  2010-05-21       Impact factor: 16.971

7.  Plasma DNA Integrity as a Prognostic Biomarker for Colorectal Cancer Chemotherapy.

Authors:  Feng Zhu; Jing Ma; Dongdong Ru; Ningning Wu; Yunhua Zhang; Huiyuan Li; Xiaoli Liu; Jianfeng Li; Huiling Zhang; Yue Xu; Jiangman Zhao; Hui Tang; Yusheng Wang; Weihua Fu
Journal:  J Oncol       Date:  2021-05-26       Impact factor: 4.375

8.  Circulating nucleic acids in plasma and serum: diagnosis and prognosis in cancer.

Authors:  Peter Brian Gahan
Journal:  EPMA J       Date:  2010-06-09       Impact factor: 6.543

9.  Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas.

Authors:  Krishna B Sriram; Vandana Relan; Belinda E Clarke; Edwina E Duhig; Morgan N Windsor; Kevin S Matar; Rishendran Naidoo; Linda Passmore; Elizabeth McCaul; Deborah Courtney; Ian A Yang; Rayleen V Bowman; Kwun M Fong
Journal:  BMC Cancer       Date:  2012-09-25       Impact factor: 4.430

10.  Multiple marker detection in peripheral blood for NSCLC diagnosis.

Authors:  Paola Ulivi; Laura Mercatali; Gian-Luca Casoni; Emanuela Scarpi; Lauro Bucchi; Rosella Silvestrini; Stefano Sanna; Marco Monteverde; Dino Amadori; Venerino Poletti; Wainer Zoli
Journal:  PLoS One       Date:  2013-02-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.